Ernest S. Smith - Mar 20, 2024 Form 4 Insider Report for VACCINEX, INC. (VCNX)

Role
SVP, Research & CSO
Signature
/s/ Maurice Zauderer, Attorney-in-Fact for Ernest S. Smith
Stock symbol
VCNX
Transactions as of
Mar 20, 2024
Transactions value $
$0
Form type
4
Date filed
3/22/2024, 04:32 PM
Previous filing
Apr 3, 2023
Next filing
May 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VCNX Common Stock 39 Mar 20, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCNX Stock Option (Right to Buy) Award $0 +1.34K $0.00 1.34K Mar 20, 2024 Common Stock 1.34K $8.32 Direct F5
holding VCNX Stock Option (Right to Buy) 193 Mar 20, 2024 Common Stock 193 $1,491.00 Direct F1
holding VCNX Stock Option (Right to Buy) 24 Mar 20, 2024 Common Stock 24 $1,491.00 Direct F1
holding VCNX Stock Option (Right to Buy) 38 Mar 20, 2024 Common Stock 38 $819.00 Direct F1
holding VCNX Stock Option (Right to Buy) 38 Mar 20, 2024 Common Stock 38 $1,274.70 Direct F1
holding VCNX Stock Option (Right to Buy) 47 Mar 20, 2024 Common Stock 47 $615.30 Direct F2
holding VCNX Stock Option (Right to Buy) 95 Mar 20, 2024 Common Stock 95 $270.90 Direct F3
holding VCNX Stock Option (Right to Buy) 190 Mar 20, 2024 Common Stock 190 $83.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Exercisable in full as of the date of this report.
F2 This option vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date, except as otherwise provided in the award notice.
F3 This option vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date, except as otherwise provided in the award notice.
F4 This option vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date, except as otherwise provided in the award notice.
F5 This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 20, 2024 grant date.

Remarks:

All figures in this Form 4 reflect the Issuer's 1-for-15 reverse stock split effected on September 25, 2023 and 1-for-14 reverse stock split effected on February 19, 2024.